Bacainn Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Phase 1, Single-Ascending-Dose Study of BT051 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BT051 100mgDrug: BT051 300mgDrug: BT051 700mgDrug: BT051 1500mgDrug: BT051 3500mgDrug: Matching Placebo
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Bacainn Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05103878
- Locations
- 🇺🇸
Spaulding Clinical Research, LLC, West Bend, Wisconsin, United States
News
No news found